A second retail growth pillar continues to rise in tune with digital sales as CCO gets on the expansion path across Australia and the US.
Pivotal trials which could position an Australian therapeutic as a leading candidate in the fight against stroke continue on pace.
Immuron heads toward a third set of Phase 2 clinical studies after pre-clinical success against a deadly infection.
Calmer Co is looking at a follow-on placement after excess demand for a scale-up amid continually improving sales.
Kava sales appear to be getting CCO close to breakeven after a massive jump in consecutively building online buys.
A rising trend of Calmer Co Kava sales goes in tune with a global megatrend of turning from alcohol to healthier alternatives.
More preclinical data showing efficacy on an animal model has Argenica further on the path toward clinical trials for traumatic brain injury.
ARG-007 trials will continue unmodified across ten Australian hospitals after no adverse events in the first five patients.
Argenica’s Liz Dallimore on clinical trials, cerebral tribulations, and dosing its first patient in the battle against stroke.
A first dosing marks the official beginning of Phase 2 clinical trials to prove ARG-007’s efficacy in treating victims of acute ischaemic stroke.